Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study

Overview of attention for article published in Frontiers in oncology, July 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 11 publications that cite this research output.

11

The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.

Clinical outcomes of immune checkpoint inhibitor combined with other targeted or immunological therapy regimens for the treatment of advanced bile tract cancer: a systematic review and meta-analysis

Article in Frontiers in Immunology (May 2024)

Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study

Article in International Journal of Surgery (May 2024)

Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma

Article in Biomedicine & Pharmacotherapy (April 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.